NEJM Evid . A Randomized Trial of Nafamostat for Covid-19

[tetano]

NEJM Evid


. 2023 Nov;2(11):EVIDoa2300132.
doi: 10.1056/EVIDoa2300132. Epub 2023 Oct 18. A Randomized Trial of Nafamostat for Covid-19

Susan C Morpeth[SUP] 1 2 [/SUP], Balasubramanian Venkatesh[SUP] 3 4 5 [/SUP], James A Totterdell[SUP] 6 [/SUP], Grace M McPhee[SUP] 7 [/SUP], Robert K Mahar[SUP] 8 9 [/SUP], Mark Jones[SUP] 10 [/SUP], Methma Bandara[SUP] 7 [/SUP], Lauren A Barina[SUP] 7 [/SUP], Bhupendra K Basnet[SUP] 11 12 [/SUP], Asha C Bowen[SUP] 13 [/SUP], Andrew J Burke[SUP] 14 15 [/SUP], Belinda Cochrane[SUP] 16 17 [/SUP], Justin T Denholm[SUP] 7 18 [/SUP], Ashesh Dhungana[SUP] 19 [/SUP], Gregory J Dore[SUP] 20 21 [/SUP], Ravindra Dotel[SUP] 22 [/SUP], Eamon Duffy[SUP] 23 24 [/SUP], Jack Dummer[SUP] 25 26 [/SUP], Hong Foo[SUP] 27 [/SUP], Timothy L Gilbey[SUP] 28 [/SUP], Naomi E Hammond[SUP] 29 30 31 [/SUP], Bernard J Hudson[SUP] 32 [/SUP], Vivekanand Jha[SUP] 5 [/SUP], Purnima R Jevaji[SUP] 33 [/SUP], Oommen John[SUP] 34 35 [/SUP], Rajesh Joshi[SUP] 33 [/SUP], Gagandeep Kang[SUP] 36 [/SUP], Baldeep Kaur[SUP] 29 [/SUP], Seungtaek Kim[SUP] 37 [/SUP], Santa Kumar Das[SUP] 38 [/SUP], Jillian S Y Lau[SUP] 39 [/SUP], Roberta Littleford[SUP] 40 [/SUP], Julie A Marsh[SUP] 13 41 [/SUP], Ian C Marschner[SUP] 42 [/SUP], Gail Matthews[SUP] 43 44 [/SUP], Michael J Maze[SUP] 45 [/SUP], Colin J McArthur[SUP] 46 [/SUP], James D McFadyen[SUP] 47 48 [/SUP], James H McMahon[SUP] 49 [/SUP], Zoe K McQuilten[SUP] 50 51 [/SUP], James Molton[SUP] 52 [/SUP], Jocelyn M Mora[SUP] 7 [/SUP], Vijaybabu Mudaliar[SUP] 33 [/SUP], Vi Nguyen[SUP] 7 [/SUP], Matthew V N O'Sullivan[SUP] 53 54 [/SUP], Suman Pant[SUP] 38 [/SUP], Jaha E Park[SUP] 55 [/SUP], David L Paterson[SUP] 56 [/SUP], David J Price[SUP] 7 8 [/SUP], Nigel Raymond[SUP] 57 58 [/SUP], Megan A Rees[SUP] 59 [/SUP], James O Robinson[SUP] 60 61 [/SUP], Benjamin A Rogers[SUP] 62 63 [/SUP], Wang-Shick Ryu[SUP] 64 [/SUP], Joe Sasadeusz[SUP] 18 [/SUP], Omar Shum[SUP] 65 66 [/SUP], Thomas L Snelling[SUP] 6 13 [/SUP], Christine Sommerville[SUP] 7 [/SUP], Nanette Trask[SUP] 67 [/SUP], Sharon R Lewin[SUP] 7 18 49 [/SUP], Thomas E Hills[SUP] 68 69 [/SUP], Joshua S Davis[SUP] 70 71 [/SUP], Jason A Roberts[SUP] 72 73 74 75 [/SUP], Steven Y C Tong[SUP] 7 18 [/SUP]



Affiliations

• PMID: 38320527
• DOI: 10.1056/EVIDoa2300132

Abstract

A Randomized Trial of Nafamostat for Covid-19Nafamostat mesylate is a potent in vitro antiviral that inhibits the host transmembrane protease serine 2 enzyme used by SARS-CoV-2 for cell entry. Morpeth et al report the results of an open-label randomized clinical trial of nafamostat for noncritically ill patients with Covid-19.


​

 

[tetano]

NEJM Evid


. 2023 Nov;2(11):EVIDe2300222.
doi: 10.1056/EVIDe2300222. Epub 2023 Oct 24. Host Receptor Targeting to Treat Covid-19

Jesper Damsgaard Gunst[SUP] 1 2 [/SUP], Ole Schmeltz Søgaard[SUP] 1 2 [/SUP]



Affiliations

• PMID: 38320534
• DOI: 10.1056/EVIDe2300222

Abstract

Not long after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the cause of coronavirus disease 2019 (Covid-19), in vitro experiments revealed that SARS-CoV-2 infection of human cells depended on the binding of the viral spike protein to the human cell-surface receptor angiotensin-converting enzyme 2 (ACE-2).[SUP]1[/SUP] Additional experiments demonstrated that infection could be blocked by inhibiting transmembrane protease, serine 2 (TMPRSS2), which is a host enzyme that cleaves the viral spike protein after binding to ACE-2 and facilitates entry of the virus into the host cell.


​